Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CTKB
Cytek Biosciences, Inc. (CTKB) Altman Z-score
Cytek Biosciences, Inc.'s Altman Z-score for fiscal 2025 is 3.89, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.89 | (1.97) |
| FY2024 | 5.86 | (2.38) |
| FY2023 | 8.24 | (1.73) |
| FY2022 | 9.97 | (4.32) |
| FY2021 | 14.29 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.68 | — | 0.82 | |
| Retained earnings / total assets | (0.22) | — | −0.31 | |
| EBIT / total assets | (0.09) | — | −0.29 | |
| Market value of equity / total liabilities | 5.38 | — | 3.23 | |
| Sales / total assets | 0.44 | — | 0.44 | |
| Altman Z-score | Safe zone | 3.89 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 6.15 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BBNX Beta Bionics, Inc. compare | 16.9× |
| INMD InMode Ltd. compare | 10.4× |
| TCMD Tactile Systems Technology, Inc. compare | 9.6× |
| SIBN SiBone compare | 7.2× |
| CTKB Cytek Biosciences, Inc. | 3.9× |
| VREX VAREX IMAGING compare | 1.7× |
| KIDS OrthoPediatrics Corp. compare | 1.5× |
| AHCO AdaptHealth Corp. compare | 0.9× |
| PACB Pacific Biosciences of California, Inc. compare | −6.0× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets